ES2056780T3 - Cepa del virus de la hepatitis, procedimiento de separacion de estas cepas y vacunas contra la hepatitis a. - Google Patents

Cepa del virus de la hepatitis, procedimiento de separacion de estas cepas y vacunas contra la hepatitis a.

Info

Publication number
ES2056780T3
ES2056780T3 ES92910019T ES92910019T ES2056780T3 ES 2056780 T3 ES2056780 T3 ES 2056780T3 ES 92910019 T ES92910019 T ES 92910019T ES 92910019 T ES92910019 T ES 92910019T ES 2056780 T3 ES2056780 T3 ES 2056780T3
Authority
ES
Spain
Prior art keywords
hepatitis
viruses
havs
strains
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910019T
Other languages
English (en)
Other versions
ES2056780T1 (es
Inventor
Reinhard Gluck
Stefan Brantschen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Schweiz Serum und Impfinstitut Bern
Schweiz Serum und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum und Impfinstitut Bern, Schweiz Serum und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten filed Critical Schweiz Serum und Impfinstitut Bern
Publication of ES2056780T1 publication Critical patent/ES2056780T1/es
Application granted granted Critical
Publication of ES2056780T3 publication Critical patent/ES2056780T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A VIRUS DE LA HEPATITIS A (HAVS) QUE TIENEN UN SEROTIPO QUE MUESTRA LAS CARACTERISTICAS INMUNOLOGICAS DE LA ESTIRPE DE HAV RG-SB XA112 (CNCM I-1080). EN PARTCULAR, LA INVENCION SE REFIERE A LA NUEVA ESTIRPE DEL VIRUS DE LA HEPATITIS A RG-SB XA112 (CNCM I-1080). LA INVENCION TAMBIEN SE REFIERE A COMPONENTES ESTRUCTURADOS DE DICHO HAVS. LOS HAVS DE LA PRESENTE INVENCION Y SUS COMPONENTES ESTRUCTURALES PUEDEN SER USADOS PARA LA PRODUCCION DE VACUNAS Y COMPOSICIONES DE DIAGNOSTICO. FINALMENTE, LA INVENCION SE REFIERE A ANTICUERPOS POLICLONALES Y MONOCLONALES QUE SON DIRIGIDOS CONTRA DICHOS NUEVOS HAVS.
ES92910019T 1991-05-08 1992-05-08 Cepa del virus de la hepatitis, procedimiento de separacion de estas cepas y vacunas contra la hepatitis a. Expired - Lifetime ES2056780T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91107526 1991-05-08
PCT/EP1992/001013 WO1992019268A1 (en) 1991-05-08 1992-05-08 New hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines

Publications (2)

Publication Number Publication Date
ES2056780T1 ES2056780T1 (es) 1994-10-16
ES2056780T3 true ES2056780T3 (es) 1998-08-16

Family

ID=8206711

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910019T Expired - Lifetime ES2056780T3 (es) 1991-05-08 1992-05-08 Cepa del virus de la hepatitis, procedimiento de separacion de estas cepas y vacunas contra la hepatitis a.

Country Status (10)

Country Link
EP (1) EP0542949B1 (es)
JP (1) JP3527238B2 (es)
AT (1) ATE163548T1 (es)
AU (1) AU662528B2 (es)
CA (1) CA2086832C (es)
DE (2) DE69224590T2 (es)
DK (1) DK0542949T3 (es)
ES (1) ES2056780T3 (es)
GR (2) GR930300089T1 (es)
WO (1) WO1992019268A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330758T2 (de) 1992-09-18 2002-07-04 Smithkline Beecham Biolog Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
EP1802746B1 (en) 2004-10-27 2011-05-04 Crucell Switzerland AG Virosome particles comprising antigens from influenza virus and hepatitis b virus
RU2405037C2 (ru) * 2008-02-12 2010-11-27 Закрытое акционерное общество "Вектор-БиАльгам" Штамм вируса гепатита а для приготовления вакцинных и диагностических препаратов
CN116514965B (zh) * 2023-06-15 2023-11-10 上海精翰生物科技有限公司 甲型肝炎病毒抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
PT71739B (en) * 1979-09-04 1982-01-26 Merck & Co Inc Process for preparing a cell culture of hepatitis a virus

Also Published As

Publication number Publication date
DE542949T1 (de) 1993-09-02
WO1992019268A1 (en) 1992-11-12
EP0542949A1 (en) 1993-05-26
ATE163548T1 (de) 1998-03-15
EP0542949B1 (en) 1998-03-04
AU662528B2 (en) 1995-09-07
DK0542949T3 (da) 1998-12-07
GR930300089T1 (en) 1993-09-30
DE69224590D1 (de) 1998-04-09
AU1743692A (en) 1992-12-21
CA2086832A1 (en) 1992-11-09
JP3527238B2 (ja) 2004-05-17
DE69224590T2 (de) 1998-10-15
GR3026612T3 (en) 1998-07-31
JPH06500238A (ja) 1994-01-13
CA2086832C (en) 2007-05-01
ES2056780T1 (es) 1994-10-16

Similar Documents

Publication Publication Date Title
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
SE9102975L (sv) Bakterofag och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
ES2065303T5 (es) Procedimiento de diagnosis y vacuna especifica.
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
ES525088A0 (es) Un procedimiento de una vacuna capaz de inducir la produccion de anticuerpos de reaccion con mas de una cepa de virus dela influenza.
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
DK158743C (da) Fremgangsmaade til fremstilling af et levende, svaekket hepatitis a virus og diagnostisk praeparat opnaaet ved fremgangsmaaden
DK0588578T3 (da) Immunogener
KR860004146A (ko) 경구용 백신의 제조방법
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
ES2056780T3 (es) Cepa del virus de la hepatitis, procedimiento de separacion de estas cepas y vacunas contra la hepatitis a.
ES2061705T3 (es) Procedimiento de obtencion de un preparado antigenico de toxoplasma gondii y sus aplicaciones diagnosticas y profilacticas.
ES2100893T3 (es) Procedimiento de preparacion de una vacuna o de un agente toxico.
ES486442A0 (es) Un metodo de preparar una vacuna que contiene una cepa ate- nuada de virus de peritonitis infecciosa felina.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
ES8701837A1 (es) Procedimiento para producir una composicion viral ateunada viva uniforme de hepatitis a.
ATE283065T1 (de) Mehrzweckvakzine gegen umhüllte viren
ES2126598T3 (es) Anticuerpos monoclonales que se fijan sobre las proteinas ns5 supuestas del virus de la hepatitis c, y procedimientos de utilizacion de estos anticuerpos.
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
Černá et al. CONTRIBUTION TO THE SER O LOGICAL, DIA (; NO S IS OF SARCO CYSTO SIS
SE8701765L (sv) Analysmetod och medel foer denna
DK0565548T3 (da) Tofasesystem til fremstilling og præsentation af fremmede antigener i levende hybridvacciner
ES2064071T3 (es) Antigeno viral de hepatitis delta, procedimiento para su purificacion y su utilizacion.
ATE177010T1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 542949

Country of ref document: ES